Updated:
enVVeno Medical Corp
enVVeno Medical Corp was established to address chronic venous insufficiency, a condition affecting millions of Americans, by engineering a permanent,...
enVVeno Medical Corp
enVVeno Medical Corp was established to address chronic venous insufficiency, a condition affecting millions of Americans, by engineering a permanent, bioprosthetic replacement venous valve. The firm is led by CEO Robert Berman and a board of directors with experience in medical-device development and commercialization. The firm's primary focus is the enVVeno Venous Valve — a device designed to replace incompetent venous valves, thereby restoring one-way blood flow and reducing symptoms such as leg swelling, pain, and ulcers. The firm conducts clinical trials in the US and Europe, seeking FDA premarket approval. As a publicly traded company (NASDAQ: NVNO), enVVeno funds operations through equity offerings and debt financing. enVVeno's team includes clinical advisors and regulatory specialists. The firm engages with medical professionals through conference presentations and peer-reviewed publications. As of 2025, the firm had reported positive one-year data from its SAVVE clinical trial, showing safety and durability of the valve implant (per the firm, 2025). A key structural differentiator is enVVeno's orphan-device designation from the FDA, which grants orphan-drug-like exclusivity and development incentives for its lead product. The firm also holds patents around its bioprosthetic valve design and delivery system, creating a narrow moat in a currently productless market.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at enVVeno Medical Corp?
enVVeno's investment decisions are managed by its board of directors and senior management, including CEO Robert Berman and CFO Brian L. Firth. The firm allocates capital toward clinical trials, regulatory submissions, and manufacturing infrastructure for its venous valve product.
What is enVVeno's lead product and current development stage?
The lead product is the enVVeno Venous Valve, a bioprosthetic replacement valve for patients with chronic venous insufficiency. As of early 2025, the firm had reported one-year outcomes from the SAVVE clinical trial, with plans to pursue FDA premarket approval.
Does enVVeno generate revenue, or is it a pre-commercial firm?
enVVeno is a pre-commercial medical-device firm with no approved products for sale. The firm does not report product revenue; its financial filings show expenses related to research, clinical development, and operations.
What regulatory designations does enVVeno hold for its venous valve?
The enVVeno Venous Valve has received orphan-device designation from the FDA, which provides development incentives, tax credits, and potential market exclusivity upon approval. This designation reflects the lack of approved alternatives for venous valve replacement.
Is enVVeno a family office, a venture firm, or a corporate entity?
enVVeno Medical Corp is a publicly traded medical-device company listed on NASDAQ under ticker NVNO. It is not a family office or investment firm but a corporate entity focused on device development and commercialization.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: